Long Term Impact of Adalimumab Therapy on Biomarkers of Systemic Inflammation in Psoriasis: Results of a 2 year study

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43920316" target="_blank" >RIV/00216208:11120/20:43920316 - isvavai.cz</a>

Alternative codes found

RIV/00064173:_____/20:N0000028

Result on the web

<a href="https://doi.org/10.1111/dth.14110" target="_blank" >https://doi.org/10.1111/dth.14110</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/dth.14110" target="_blank" >10.1111/dth.14110</a>

Result language

angličtina

Original language name

Long Term Impact of Adalimumab Therapy on Biomarkers of Systemic Inflammation in Psoriasis: Results of a 2 year study

Original language description

Psoriasis patients are at increased risk of atherosclerosis, characterized by endothelial dysfunction, linked through systemic inflammation. Anti-TNF-a therapy seems to decrease this risk. The purpose of this study was to measure the levels of serum markers associated with systemic inflammation in psoriasis patients, compared to healthy individuals and to investigate the change in their levels after 3 months and 2 years of adalimumab therapy. We investigated 4 biomarkers: high-sensitivity C-reactive protein (hsCRP), oxidized low-density lipoproteins (OxLDL), E-selectin and Interleukin 22 (IL-22). These markers were measured in healthy volunteers and in 28 patients with moderate/severe psoriasis before and after 3 and 24 months of treatment with adalimumab. Psoriasis patients had increased levels of markers in comparison to the control group. After 3 months of therapy, E-selectin decreased significantly (P &lt; 0.001), as well as IL-22 (P &lt; 0.001). hsCRP also decreased but did not show a statistical significance, OxLDL were slightly higher than initially. After 24 months, 17 patients were still being treated with adalimumab. In these patients, hsCRP (P &lt; 0.05), E-selectin (P &lt; 0.001) and IL-22 (P &lt; 0.001) were significantly decreased. OxLDL remained at a higher level. The stable decrease of E-selectin, hsCRP and IL-22 after 24 months confirms that adalimumab suppresses systemic inflammation.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Dermatologic Therapy

ISSN

1396-0296

e-ISSN

—

Volume of the periodical

33

Issue of the periodical within the volume

6

Country of publishing house

US - UNITED STATES

Number of pages

6

Pages from-to

"Article e14110"

UT code for WoS article

000560662900001

EID of the result in the Scopus database

2-s2.0-85089455762